Moomoo AI 已提取核心訊息
Bristol-Myers Squibb Company, a leading pharmaceutical company, announced a significant change in its executive team. Effective February 15, 2024, Mr. Phil Holzer has been appointed as the new Senior Vice President and Controller. Mr. Holzer, who has been with the company since 2001, has held various senior roles, most recently serving as Senior Vice President, Finance, Treasury, and Tax Operations from 2021 to 2024. His extensive experience within the company includes positions such as Chief Audit Officer and Vice President, U.S. Commercialization Finance. The outgoing Senior Vice President and Controller, Ms. Sharon Greenlees, will transition to another role within the company on the same date. The announcement confirms that Mr. Holzer has no familial ties with any director or executive officer of the company and is not involved in any transaction that would require disclosure under SEC regulations.
Bristol-Myers Squibb Company, a leading pharmaceutical company, announced a significant change in its executive team. Effective February 15, 2024, Mr. Phil Holzer has been appointed as the new Senior Vice President and Controller. Mr. Holzer, who has been with the company since 2001, has held various senior roles, most recently serving as Senior Vice President, Finance, Treasury, and Tax Operations from 2021 to 2024. His extensive experience within the company includes positions such as Chief Audit Officer and Vice President, U.S. Commercialization Finance. The outgoing Senior Vice President and Controller, Ms. Sharon Greenlees, will transition to another role within the company on the same date. The announcement confirms that Mr. Holzer has no familial ties with any director or executive officer of the company and is not involved in any transaction that would require disclosure under SEC regulations.
領先的製藥公司百時美施貴寶公司宣佈其執行團隊進行重大變動。自2024年2月15日起，菲爾·霍爾澤先生被任命爲新的高級副總裁兼財務總監。霍爾澤先生自2001年以來一直在公司工作，曾擔任過各種高級職務，最近在2021年至2024年期間擔任財務、財政和稅務運營高級副總裁。他在公司的豐富經驗包括首席審計官和美國商業化融資副總裁等職位。即將離任的高級副總裁兼財務總監莎朗·格林利斯女士將於同日調任公司內部的另一個職位。該公告證實，霍爾澤先生與公司的任何董事或執行官都沒有家族關係，也沒有參與任何根據美國證券交易委員會法規需要披露的交易。
領先的製藥公司百時美施貴寶公司宣佈其執行團隊進行重大變動。自2024年2月15日起，菲爾·霍爾澤先生被任命爲新的高級副總裁兼財務總監。霍爾澤先生自2001年以來一直在公司工作，曾擔任過各種高級職務，最近在2021年至2024年期間擔任財務、財政和稅務運營高級副總裁。他在公司的豐富經驗包括首席審計官和美國商業化融資副總裁等職位。即將離任的高級副總裁兼財務總監莎朗·格林利斯女士將於同日調任公司內部的另一個職位。該公告證實，霍爾澤先生與公司的任何董事或執行官都沒有家族關係，也沒有參與任何根據美國證券交易委員會法規需要披露的交易。
有用
沒用